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Abstract: 
Neurocysticercosis (NC) or infection of the central nervous system with 
Taenia solium larvae is the leading cause of preventable epilepsy in 
endemic regions across the globe.  Albendazole and praziquantel are 
commonly used antihelminthic agents to treat NC; however, viable cysts 
persist in the majority of patients, putting them at risk for future seizures 
and other neurological complications.    
 
Because of their pharmacokinetic profiles, albendazole and praziquantel 
have the potential to interact with many different drugs.  During 
antihelminthic treatment, antiepileptic drugs and corticosteroids are 
commonly co-administered to manage seizures and cerebral edema; 
however, the most commonly used agents from these drug classes are 
known to significantly alter plasma concentrations of albendazole and 
praziquantel.  
 
The overarching issue with drug interactions during the treatment of NC is 
whether or not they have clinical relevance, as the plasma concentrations 
of albendazole and praziquantel have not been directly linked with 
eradication of viable cysts.  Future studies should attempt to evaluate the 
validity of a causal relationship between antihelminthic plasma 
concentrations and outcomes so that drug interactions can be better 
understood and managed and so that treatment can be optimized.  
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 47 
Abstract 48 
Neurocysticercosis (NC) or infection of the central nervous system with Taenia solium 49 
larvae is the leading cause of preventable epilepsy in endemic regions across the globe.  50 
Albendazole and praziquantel are commonly used antihelminthic agents to treat NC; 51 
however, viable cysts persist in the majority of patients, putting them at risk for future 52 
seizures and other neurological complications.   53 
 54 
Because of their pharmacokinetic profiles, albendazole and praziquantel have the 55 
potential to interact with many different drugs.  During antihelminthic treatment, 56 
antiepileptic drugs and corticosteroids are commonly co-administered to manage seizures 57 
and cerebral edema; however, the most commonly used agents from these drug classes 58 
are known to significantly alter plasma concentrations of albendazole and praziquantel.  59 
 60 
The overarching issue with drug interactions during the treatment of NC is whether or not 61 
they have clinical relevance, as the plasma concentrations of albendazole and 62 
praziquantel have not been directly linked with eradication of viable cysts.  Future studies 63 
should attempt to evaluate the validity of a causal relationship between antihelminthic 64 
plasma concentrations and outcomes so that drug interactions can be better understood 65 
and managed and so that treatment can be optimized. 66 
 67 
 68 
 69 
 70 
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 3 
Introduction 71 
Neurocysticercosis (NC), or central nervous system infection with the larval form of the 72 
cestode tapeworm Taenia solium, is the leading cause of preventable epilepsy in endemic 73 
regions of Africa, Asia, and Latin America.
1
  In addition, cases of NC are increasingly 74 
seen in the United States and the European Union, as both have high immigration rates 75 
from endemic regions.
2,3
  NC develops when T. solium eggs are ingested through the 76 
fecal-oral route (i.e., autoinfection or person-to-person transmission), cross the digestive 77 
tract into the blood stream and encyst in the central nervous system where they evolve 78 
through  4 stages.
4,5
  After encysting, the vesicular stage begins, where the larva remains 79 
alive, protected by the cyst.
4
  With natural evolution, the colloidal stage follows, where 80 
the cyst begins to degenerate, which is followed by the granular-nodular stage, where the 81 
wall of the cyst beings to thicken, and finally the calcified stage.
4
  Cysts are only viable 82 
during the vesicular and colloidal stages, which are the only stages that respond to 83 
antihelminthic treatment.
4
  NC may affect the brain parenchyma or infiltrate the 84 
cerebrospinal fluid primarily of the subarachnoid spaces and ventricles (i.e., 85 
extraparenchymal NC).  The parenchymal location generally has a good prognosis; 86 
however, in contrast, the extraparenchymal location is associated with high morbidity and 87 
mortality.
5
  88 
 89 
Antihelminthic treatment appears to have a role in reducing the number of viable cysts 90 
and potentially reducing the risk of seizures in patients with parenchymal NC.
4
 It has 91 
been argued that the most important issue in the efficacy of NC treatment is the complete 92 
disappearance of cysts, as viable cysts eventually evolve into calcifications, which are 93 
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 4 
associated with increased risk for recurrent seizures and are not treatable with 94 
antihelminthic agents.
6
  Two antihelminthic agents, albendazole and praziquantel, are 95 
used in clinical practice for the treatment of NC. Recent evidence-based guidelines found 96 
insufficient evidence to assess the efficacy of praziquantel, but currently recommend 97 
albendazole for the treatment of NC in both adults and children.
4
 Of interest is that the 98 
dose and duration of antihelminthic regimens, even those tested in clinical trials, are 99 
empiric and have not been optimized through evidence-based research.  Despite the 100 
availability of these two agents, cure rates remain suboptimal. In large clinical trials, 101 
treatment with albendazole only led to disappearance of viable cysts in about one-third of 102 
patients, after a first course of therapy.
7,8
 103 
 104 
Antihelminthic treatment leads to degradation of encysted larvae by making the larvae 105 
recognizable to the host’s immune system.  During treatment, the host immune response 106 
against the cyst often leads to cerebral edema and consequently seizures.  Corticosteroids 107 
are routinely used to control edema and antiepileptic drugs (AEDs) are often used for 108 
prevention of seizures, and both are commonly coadminist red during antihelminthic 109 
treatment of NC.
4,7
 The objective of this review is to evaluate the current evidence for 110 
common drug interactions with albendazole and praziquantel during treatment of NC and 111 
to identify gaps in the existing scientific literature. 112 
 113 
Pharmacokinetics of Albendazole 114 
Albendazole has low bioavailability after oral administration, which may be related to 115 
poor absorption due to limited solubility.
9
 After absorption, albendazole is subject to 116 
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 5 
rapid and extensive first-pass metabolism into the chiral metabolite, albendazole 117 
sulfoxide, which is the entity responsible for its cysticidal activity.
10
 The (+),-enantiomer 118 
of albendazole sulfoxide has the greatest pharmacologic activity against T. solium.
11
 119 
Albendazole is subject to high intrinsic clearance
12
 which may be a result of poor 120 
absorption, extensive first pass metabolism, or a combination of these factors. 121 
Albendazole sulfoxide also exhibits a degree of plasma protein binding (62%-72%).
13
 122 
Flavin-containing monooxygenases and cytochrome P450 (CYP) 3A isoenzymes are 123 
responsible for the first pass hepatic metabolism of albendazole into albendazole 124 
sulfoxide.
10
 Albendazole sulfoxide is then converted into an inactive metabolite, 125 
albendazole sulfone, a process that is also mediated by CYP450; however, the precise 126 
isoforms responsible for this process remain unclear.
10,14,15
 Because of the involvement of 127 
CYP 3A isoenzymes in the formation of the active metabolite, it is not surprising that 128 
inhibitors of CYP 3A, such as ritonavir, as well as inducers, such as phenytoin, may 129 
influence plasma concentrations of albendazole sulfoxide.
16,17
   130 
 131 
The pharmacokinetics of albendazole are subject to high interpatient variability. The 132 
population pharmacokinetics of albendazole were prospectively evaluated in a study by 133 
Castro et al. in which 90 patients with NC received a standard regimen of 30 mg/kg/day 134 
for 8 days.
18
 In about one-quarter of patients, the bioavailability of albendazole was only 135 
28%, compared with complete bioavailability modeled in roughly three-quarters of 136 
patients.  This substantial difference in bioavailability between this subpopulation and the 137 
rest of the study participants was not accounted for by covariates such as age, sex, or 138 
creatinine clearance, and concomitant drugs.  Concurrent diet was not described in this 139 
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study, which may have affected albendazole sulfoxide plasma concentrations.  The low 140 
exposures of albendazole sulfoxide in a substantial subpopulation observed in this study 141 
should be considered as a possible reason for the suboptimal efficacy of albendazole in 142 
some patients with NC.
18
  143 
 144 
Pharmacokinetics of Praziquantel  145 
Praziquantel is a highly lipophilic molecule and is well-absorbed from the gastrointestinal 146 
tract.
19
  It is administered as a racemic mixture, with (–)-(R)-praziquantel being the 147 
pharmacologically active enantiomer.
20
 Praziquantel is metabolized by hepatic CYP 1A, 148 
CYP 3A and CYP 2C isoenzymes into inactive hydroxylated compounds.
12
 Similar to 149 
albendazole, praziquantel is also subject to high intrinsic clearance, but in contrast, this is 150 
probably due to its extensive first pass metabolism, rather than poor absorption.  151 
Although its distribution has not been extensively studied, it has been reported that 152 
praziquantel is 80% to 85% bound by plasma proteins.
13
 The metabolism of praziquantel 153 
makes certain drug-drug interactions easier to assess because unlike albendazole for 154 
which CYP450 isoenzymes are involved in the formation of both the active and inactive 155 
metabolite, with praziquantel, CYP450 isoenzymes are only involved in the conversion 156 
of the active into the inactive metabolite.  Drugs that inhibit CYP 3A isoenzymes, such as 157 
ketoconazole, and drugs that induce CYP 3A, such as rifampin, may significantly 158 
influence plasma concentrations of praziquantel.
21,22
  159 
 160 
Drug Interactions with Antiepileptic Drugs 161 
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 7 
First generation AEDs—phenobarbital, phenytoin, and carbamazepine—are potent 162 
inducers of CYP isoenzymes, including 3A and 1A
23
, of which CYP 3A isoenzymes are 163 
involved in the metabolism of both albendazole and praziquantel and 1A isoenzymes are 164 
involved in the metabolism of praziquantel. In addition, first generation AEDs have high 165 
plasma protein binding.
24
  AEDs are often needed for prevention and treatment of 166 
seizures during antihelminthic treatment of NC because the inflammatory response to 167 
treatment may induce seizures and also because new onset epilepsy may have been the 168 
event that led to a diagnosis of NC.  Drug-drug interaction studies have shown that there 169 
is a significant pharmacokinetic interaction between AEDs and antihelminthic agents.  170 
 171 
Lanchote et al. evaluated the pharmacokinetic interaction between AEDs and albendazole 172 
in a study that included patients with parenchymal NC and viable cysts.
17
  Patients 173 
received albendazole (7.5 mg/kg every 12 hours) for 8 days and were divided by their 174 
AED use for at least the last 3 months: no AED, phenytoin, carbamazepine, or 175 
phenobarbital. In addition, 40% of patients received dexamethasone, during treatment 176 
with albendazole for control of cerebral edema.  Despite th  high interindividual 177 
variability of albendazole metabolite concentrations in the plasma, all 3 antiepileptic 178 
drugs significantly reduced the mean maximum concentration (Cmax) and area under the 179 
concentration-time curve (AUC) of (+),-albendazole sulfoxide after 8 days of therapy 180 
(Table 1).  Reduced bioavailability may have been explained by increased extraction 181 
upon first pass metabolism secondary to the CYP inducing effects of AEDs on 182 
albendazole.  However, the role of plasma protein binding should also be considered 183 
because phenytoin, carbamazepine, and phenobarbital have high plasma protein binding 184 
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 8 
(>80%)
24
 and albendazole sulfoxide also binds to plasma proteins, albeit to a smaller 185 
degree (62% to 72%).
13
    Because half-life was also significantly reduced when AEDs 186 
were coadministered with albendazole, it is a possibility that the unbound fraction of 187 
albendazole sulfoxide was increased due to competition for plasma proteins with AEDs 188 
and free albendazole sulfoxide was subsequently cleared extensively, leading to a 189 
reduction in half-life.  In addition, it is known that dexamethasone can significantly 190 
increase plasma concentrations of albendazole sulfoxide
25,26
 and although a subgroup 191 
analysis was not described, this did not appear to counteract effect of AEDs on reducing 192 
plasma concentrations of albendazole sulfoxide.
17
   193 
 194 
As is the case with albendazole, plasma concentrations of praziquantel are significantly 195 
reduced by coadministration of AEDs (Table 1).  In a study by Bittencourt et al., epileptic 196 
patients without NC who were stable on monotherapy of phenytoin or carbamazepine for 197 
at least 6 months and healthy controls both received a single dose of praziquantel (25 198 
mg/kg).
27
  Unlike the study by Lanchote et al. that evaluated albendazole, the 199 
pharmacokinetics of specific enantiomers of praziquantel were not evaluated.  The AUC 200 
and Cmax of praziquantel in patients receiving carbamazepine or phenytoin were 201 
significantly lower compared with patients not receiving AEDs.  Tmax was not 202 
significantly different between groups, suggesting that the drug interaction was not 203 
related to absorption.  Aside from induction of first-pass hepatic metabolism, it is a 204 
possibility that phenytoin and carbamazepine may also play a role in displacing 205 
praziquantel from plasma protein binding sites, as with albendazole, leading to an 206 
increase in the unbound fraction of praziquantel and subsequent extensive clearance.
27
  207 
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 9 
Cimetidine has been used in some cases to counteract the drug interaction between 208 
praziquantel and AEDs;
28
 however, this approach has not been evaluated prospectively. 209 
 210 
An important limitation of these studies is that they were not crossover studies
17,27
, so it 211 
difficult to account for interpatient pharmacokinetic variability, which is particularly high 212 
with albendazole.
18
 Additionally, CYP 3A isoenzyme activity is variable and thus, 213 
different levels of CYP 3A induction would be expected among different patients.   214 
 215 
In clinical trials evaluating antihelminthic treatment of NC, primarily phenytoin and 216 
carbamazepine have been used for seizure control.
7,8
 The use of newer AEDs, which do 217 
not induce CYP enzymes and have lower plasma protein binding, may warrant further 218 
evaluation for use during treatment of NC to see if their use has any differential effect on 219 
cyst reduction.  There is increasing clinical experience and evidence with newer AEDs
29
; 220 
however, there is little published data on their use specifically in NC. An additional 221 
consideration relevant in the context of treating NC is that newer AEDs may not be on 222 
Essential Medicines Lists in endemic countries and their costs may be prohibitive for 223 
many patients in low resource settings.
30
  224 
 225 
Drug Interactions with Corticosteroids 226 
Corticosteroids are subject to a variety of drug-drug interactions related to their 227 
metabolism by CYP isoenzymes.
31
  For example, AEDs can significantly reduce plasma 228 
concentrations of prednisolone and methylprednisolone.
31
  Corticosteroids are routinely 229 
administered during antihelminthic treatment to reduce the cerebral edema that results 230 
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from degenerating cysts. However, it appears that albendazole and praziquantel interact 231 
differently with dexamethasone. 232 
 233 
A study by Jung et al. demonstrated that coadministration of dexamethasone significantly 234 
increased plasma concentrations of albendazole sulfoxide in patients with NC.
25
 In this 235 
study, albendazole was given at a dose of 15 mg/kg divided into three daily doses for 8 236 
days, followed by another 8 days when dexamethasone 8 mg was given with each dose of 237 
albendazole.  The mean plasma concentration of albendazole sulfoxide during the first 8 238 
days without concurrent dexamethasone was 728 ng/mL (range 169 ng/mL to 2268 239 
ng/mL), which increased by 56% to a mean of 1253 ng/mL (range 306 ng/mL to 1934 240 
ng/mL) during the last 8 days when dexamethasone was given concurrently.  Of the 8 241 
patients in this study, all patients except one had increased albendazole sulfoxide plasma 242 
concentrations when dexamethasone was added (range: -9% to 592%).
25
  A larger sample 243 
size may have helped determine if this increase in albendazole sulfoxide plasma 244 
concentrations could be at least partially explained by interpatient variability. 245 
 246 
Similarly, a study that compared an 8-day course of albendazole alone, albendazole with 247 
dexamethasone, and albendazole with dexamethasone and cimetidine in patients with NC 248 
found that dexamethasone significantly increased plasma concentrations of albendazole 249 
sulfoxide.
26
  The group receiving albendazole with dexamethasone had a median steady-250 
state AUC of albendazole sulfoxide that was significantly higher compared with the 251 
group that received albendazole monotherapy (4.7 mcg/h/mL vs. 2.3 mcg/h/mL; P<.05).  252 
This study also evaluated oral clearance (CL/F) of albendazole sulfoxide, which was 253 
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roughly one-third lower in participants receiving concurrent dexamethasone compared 254 
with patients receiving albendazole monotherapy (1.05 L/h/Kg vs. 3.02 L/h/Kg; P<.05). 255 
The lower clearance observed with concurrent dexamethasone suggests that 256 
dexamethasone increases plasma concentrations of albendazole sulfoxide by decreasing 257 
its clearance, rather than affecting its formation. The pharmacokinetic profile of 258 
albendazole sulfoxide was similar between the group receiving cimetidine with 259 
albendazole and dexamethasone and the group receiving albendazole and dexamethasone 260 
alone, suggesting that the increase in plasma concentrations was mainly due to the 261 
addition of dexamethasone.  As this was not a crossover study, it is also important to 262 
consider the role of differences in drug disposition between patients as a potential source 263 
of bias.
26
  264 
 265 
Unlike with albendazole, dexamethasone may significantly reduce plasma concentrations 266 
of praziquantel.  In a study by Vazquez et al., 8 patients with parenchymal NC began to 267 
receive dexamethasone half-way through a 2 week course of praziquantel.
32
 268 
Simultaneous administration of both drugs significantly reduced mean praziquantel 269 
concentrations at steady state compared to when praziquantel was administered alone (3.1 270 
± 0.1 mcg/mL vs 1.6 ± 0.6 mcg/mL; P<.001).  This was a consistent effect, with 271 
reductions in praziquantel plasma concentrations observed in all patients. The potential 272 
mechanism for this interaction remains unclear, as clearance was not evaluated in this 273 
study.
32
  274 
 275 
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In our review of the literature, only drug-drug interaction studies with dexamethasone 276 
were identified.  In clinical practice, other agents such as prednisolone are also often 277 
used.  Because the mechanism of the drug interactions with dexamethasone is unclear, 278 
the potential effect of other corticosteroids on the pharmacokinetics of albendazole and 279 
praziquantel is unknown and should be studied. 280 
 281 
Drug Interactions with Histamine-2 Antagonists and Proton Pump Inhibitors 282 
Histamine-2 antagonists and proton pump inhibitors are often used to prevent the gastric 283 
toxicity of corticosteroids in patients being treated for NC.  As these agents can increase 284 
gastric pH, their use can significantly alter the absorption of drugs that are absorbed only 285 
at specific pH levels.  In the literature, we only identified studies that evaluate drug-drug 286 
interactions between albendazole and praziquantel with cimetidine.  Additional studies 287 
are needed that evaluate interactions with more commonly used histamine-2 antagonists 288 
such as ranitidine, and proton pump inhibitors. 289 
 290 
The absorption of albendazole may be pH dependent, as demonstrated by a drug 291 
interaction study with cimetidine (a histamine-2 antagonist and CYP 3A inhibitor) and 292 
grapefruit juice (a CYP 3A inhibitor).
33
  In this study, administration of grapefruit juice 293 
alone with albendazole increased albendazole sulfoxide Cmax and AUC significantly, 294 
suggesting that albendazole is subject to mucosal CYP 3A isoenzyme metabolism. The 295 
role of grapefruit juice in activating P-glycoprotein (P-gp) to modulate the bioavailability 296 
of albendazole has also been considered; however, it does not appear that albendazole 297 
interacts with P-gp.
34
  In contrast, concurrent administration of grapefruit juice and 298 
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cimetidine decreased the Cmax of albendazole from 0.8 ± 0.5 mg/L to 0.4 ± 0.3 mg/L (P= 299 
.022) and AUC0-inf from 6.5 ± 5.1 mg/h/L to 3.5 ± 1.9 mg/h/L (P=.118) compared with 300 
grapefruit juice alone. Although it may seem paradoxical that coadministration of two 301 
CYP 3A isoenzyme inhibitors decreases plasma concentrations of a CYP 3A substrate, 302 
this reduction in Cmax may actually be the result of inhibition of gastric acid secretion by 303 
cimetidine, suggesting that absorption of albendazole is pH dependent.
33
  However, in the 304 
absence of a comparator group that only received cimetidine, this hypothesis is difficult 305 
to support because cimetidine has not always shown a significant pharmacokinetic effect 306 
when added to albendazole.
26
  307 
 308 
Unlike albendazole, it does not appear that the absorption of praziquantel is pH 309 
dependent.  In a crossover study evaluating the interaction between cimetidine and 310 
praziquantel, coadministration of both agents after 3 doses increased mean Cmax from 1.8 311 
± 0.7 mcg/mL to 3.7 ± 1.5 mcg/mL, mean AUC from 6.6 ± 2.5 mcg/mL/h to 11.5 ± 4.6 312 
mcg/mL/h and increased mean t1/2 from 1.8 ± 0.5 hours to 2.4 ± 0.6 hours (P<.05 for all 313 
comparisons).
35
 Tmax did not significantly increase, suggesting that the addition of 314 
cimetidine did not affect the absorption of praziquantel and that this drug-drug interaction 315 
was mediated by CYP 3A inhibition.
35
   316 
 317 
Drug Interactions with Food 318 
Concurrent diet may be an important consideration during antihelminthic treatment 319 
because food can have a significant effect on plasma concentration of both albendazole 320 
and praziquantel.  A two-way crossover study of 16 healthy volunteers evaluated the 321 
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effect of a high-fat meal (61.1 g total fat) with a single 800 mg dose of albendazole.
36
  322 
Compared with the fasting state, a high-fat meal increased albendazole sulfoxide Cmax 323 
from 0.26 ± 0.1 mcg/mL to 1.8 ± 0.6 mcg/mL, AUC0-inf from 5.1 ± 2.8 mcg/h/mL to 29.4 324 
± 14.6 mcg/h/mL, and Tmax from 3.2 ± 1.1 hours to 5.1 ± 1.6 hours (P<.05 for all 325 
comparisons).  In contrast, CL/F was reduced from 0.2 ± 0.2 mL/h (fasting) to 0.04 ± 326 
0.02 mL/h (high fat meal), as well as volume of distribution (Vd/F), 3.0 ± 1.9 mL 327 
(fasting) to 0.4 ± 0.2 mL (high fat meal) (P<.05 for both comparisons). Although a high 328 
fat meal increased plasma concentrations of albendazole sulfoxide, there was significant 329 
variability in pharmacokinetics among the participants of this study.  This variability may 330 
be influenced by additional factors, such as differences in gastric pH and drug 331 
metabolism.
36
    332 
 333 
Similar to albendazole, concomitant administration of food with praziquantel has a 334 
significant effect on its plasma concentrations.  In a study by Castro et al., healthy 335 
volunteers were randomly assigned to receive praziquantel 1800 mg with a high fat meal, 336 
a high carbohydrate meal, or after 10 hours of fasting.
37
 M an Cmax was 318.8 ± 227.2 337 
ng/mL among fasting participants compared with 1095.4 ± 780.0 ng/mL for participants 338 
receiving the high fat meal and 1962.2 ± 779.8 ng/mL for participants receiving the high 339 
carbohydrate meal (P<.05 for both comparisons).  Mean AUC0-8 was 882.3 ± 416.8 340 
ng/h/mL among fasting participants compared with 2474.6 ± 1166.0 ng/h/mL for 341 
participants receiving the high fat meal and 3276.2±969.7 ng/h/mL for participants 342 
receiving the high carbohydrate meal (P<.05 for both comparisons). Since the high fat 343 
meal also contained a high amount of carbohydrates, it is possible that it was the 344 
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carbohydrates and not the fats that caused the increase in the bioavailability of 345 
praziquantel.
37
  346 
 347 
The mechanisms for the drug-food interactions with albendazole and praziquantel are 348 
unclear.  In the case of albendazole, the increased plasma concentrations may have been a 349 
result of increased intestinal absorption, because a fatty meal increased the plasma 350 
concentrations of the active metabolite, albendazole sulfoxide.  However, plasma 351 
concentrations of the parent compound were not evaluated and thus other processes, such 352 
as increased lymphatic absorption, cannot be ruled out.  With praziquantel, the 353 
mechanism for this interaction is even less clear and may result from many potential 354 
processes including increased intestinal absorption, increased lymphatic absorption, or 355 
enhanced lipoprotein binding. As NC affects many diverse endemic regions, it is 356 
important to also consider local diet when interpreting these studies.  357 
 358 
Clinical Relevance of Plasma Concentrations of Albendazole and Praziquantel 359 
During Treatment of NC 360 
Based on the available literature, both unidentified causes of pharmacokinetic variability 361 
and drug interactions may significantly affect plasma concentrations of albendazole and 362 
praziquantel.  Monitoring of plasma concentrations of albendazole and praziquantel is 363 
possible;
20
 however, the clinical relevance of trough and peak plasma concentrations of 364 
either drug has not been established. Even if routine therapeutic drug monitoring is a 365 
possibility, it may not be realistic for clinical practice in some low resource primary care 366 
settings.   367 
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 368 
The overarching issue with drug interactions during the treatment of NC is that the 369 
clinical importance of albendazole and praziquantel plasma concentrations has not been 370 
firmly established.  A study that showed a single day of high dose praziquantel compared 371 
with a standard weeklong regimen of albendazole was effective for treating NC provides 372 
some anecdotal evidence that the cysticidal activity of praziquantel may be dose 373 
dependent and therefore, plasma concentrations may be clinically important.
38
  However, 374 
a study of 29 patients did not find any correlation between plasma concentrations of 375 
albendazole and praziquantel and cysticidal efficacy at 3 months.
39
  What limits the 376 
generalizability of this study is that the majority of the patients with an available 3 month 377 
CT scan had complete disappearance of cysts, which is a finding that has not been 378 
observed in large randomized controlled trials.
7,8
 Plasma concentrations of albendazole 379 
and praziquantel should be taken and analyzed in future, large clinical trials to provide 380 
stronger evidence to evaluate the validity of a causal relationship between antihelminthic 381 
plasma concentrations and reduction in cysts.   382 
 383 
Conclusions and Future Directions 384 
Based on the available literature, there are significant route drug and food interactions 385 
during treatment of NC with albendazole and praziquantel.  Given the paucity of 386 
outcome-based data, it is not possible to make evidence-based recommendations for 387 
managing drug interactions with albendazole and praziquantel in patients with NC. 388 
Studies are needed that provide evidence-based strategies for managing drug interactions 389 
in NC (e.g., increasing or reducing the dose of antihelminthic agents).  Furthermore, the 390 
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clinical relevance of plasma concentrations of albendazole and praziquantel during 391 
treatment of NC needs to be determined, so that the drug interactions can be better 392 
understood and managed and current antihelminthic treatment can be optimized.  393 
 394 
 395 
 396 
 397 
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Table 1. Effect of antiepileptic drugs on albendazole sulfoxide and praziquantel pharmacokinetics17,27 
* P<.05; † P<.01. 
 
 
 Albendazole 
control 
(n=9) 
Phenytoin 
+ 
albendazole 
(n=9) 
Carbamazepine 
+  
albendazole 
(n=9) 
Phenobarbital 
+ 
albendazole 
(n=5) 
 Praziquantel 
control 
(n=10) 
Phenytoin  
+ 
praziquantel 
(n=10) 
Carbamazepine 
+  
praziquantel 
(n=10) 
Mean 
Cmax 
(ng/mL) 
807.2 
(538.5-
1075.9) 
279.4* 
(171.9-
386.6) 
408.4* 
(275.9-540.8) 
286.5* 
(39.5-612.5) 
1550 
(311-4735) 
375† 
(31-1170) 
122† 
(51-275.3) 
Mean 
AUC 
(ng*h/mL) 
6123.1 
(3270.3-
8975.9) 
2115.4* 
(1316.7-
2914.1) 
3098.2* 
(1924.7-
4271.7) 
2432.4* 
(146.1-
4718.7) 
3270 
(920-5780) 
853† 
(55-1900) 
318† 
(111-648) 
Mean t1/2 
(h) 
8.0 
(5.8-10.2) 
3.8* 
(2.5-5.2) 
4.1* 
(3.0-5.2) 
4.9 
(1.3-8.5) 
1.9 
(1.4-2.4) 
1.7 
(0.8-2.0) 
1.7 
(1.2-2.6) 
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